- Home
- IVVD vs CLLS Comparison
IVVD vs CLLS Comparison
Compare IVVD & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- CLLS
- Stock Information
- Founded
- IVVD 2020
- CLLS 1999
- Country
- IVVD United States
- CLLS France
- Employees
- IVVD N/A
- CLLS N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- CLLS Health Care
- Exchange
- IVVD Nasdaq
- CLLS Nasdaq
- Market Cap
- IVVD 123.8M
- CLLS 144.4M
- IPO Year
- IVVD 2021
- CLLS 2007
- Fundamental
- Price
- IVVD $0.65
- CLLS $1.58
- Analyst Decision
- IVVD Strong Buy
- CLLS Buy
- Analyst Count
- IVVD 3
- CLLS 3
- Target Price
- IVVD $7.52
- CLLS $7.00
- AVG Volume (30 Days)
- IVVD 1.8M
- CLLS 79.4K
- Earning Date
- IVVD 05-15-2025
- CLLS 05-27-2025
- Dividend Yield
- IVVD N/A
- CLLS N/A
- EPS Growth
- IVVD N/A
- CLLS N/A
- EPS
- IVVD N/A
- CLLS N/A
- Revenue
- IVVD $25,384,000.00
- CLLS $49,217,000.00
- Revenue This Year
- IVVD $606.63
- CLLS $48.52
- Revenue Next Year
- IVVD $83.30
- CLLS $5.17
- P/E Ratio
- IVVD N/A
- CLLS N/A
- Revenue Growth
- IVVD N/A
- CLLS 435.38
- 52 Week Low
- IVVD $0.36
- CLLS $1.10
- 52 Week High
- IVVD $2.74
- CLLS $3.32
- Technical
- Relative Strength Index (RSI)
- IVVD 52.71
- CLLS 60.44
- Support Level
- IVVD $0.52
- CLLS $1.46
- Resistance Level
- IVVD $0.80
- CLLS $1.65
- Average True Range (ATR)
- IVVD 0.08
- CLLS 0.08
- MACD
- IVVD 0.01
- CLLS -0.00
- Stochastic Oscillator
- IVVD 50.70
- CLLS 75.00
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.